Raloxifene and Risk for Stroke Based on the Framingham Stroke Risk Score

Incidence of A) nonfatal stroke, and B) fatal stroke among participants in the MORE trial, and by quartiles of baseline Framingham stroke risk score for RUTH participants. HR=hazard ratio (95% confidence interval). Note: MORE data are shown as placebo versus pooled raloxifene 60 mg and 120 mg dose groups (ie, approximately twice as many women assigned to raloxifene as placebo). P-values are for test for interaction of hazard ratio with quartile of Framingham Stroke Risk Score in RUTH. MORE=Multiple Outcomes of Raloxifene Evaluation; RUTH=Raloxifene Use for The Heart.

Absolute difference (per 1000 woman-years) in incidence of fatal stroke (raloxifene compared with placebo) among participants in the MORE trial and by quartile of Framingham Stroke Risk Score in RUTH. FSRS=Framingham stroke risk score; MORE=Multiple Outcomes of Raloxifene Evaluation; RUTH=Raloxifene Use for The Heart.

Cumulative incidence curves for fatal stroke for RUTH trial participants at A) higher or B) lower risk for stroke, as determined by the Framingham stroke risk score. P-value for interaction between the effect of treatment and higher vs lower baseline Framingham stroke risk score=0.33. The absolute risk difference (raloxifene vs placebo) was: 1.3 (95% CI, 0.05-2.5) events per 1000 woman-years in the higher risk group and 0.07 (95% CI, −0.8-0.8) events per 1000 woman-years in lower risk group. RUTH=Raloxifene Use for The Heart; HR=hazard ratio; CI=confidence interval.